🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

How does AR activation affect gene expression? Our new paper shows it’s less about creating new loops and more about amplifying contact frequency in existing ones. Explore in Nature Communications (rdcu.be/dYYOL) Tweetorial below: #AR #Epigenetics #prostatecancer

Our paper out today in Nature Communications analyzed plasma from the phase 3 Alliance for Clinical Trials in Oncology A031201 trial using the AR-ctDETECT assay. Patients positive for circulating tumor DNA had poor overall survival despite treatment with potent AR inhibitors. rdcu.be/d28wf

The last time Felix stood on our stage, after a beautiful talk by Misha Beltran & intro by @AminaZoubeidi 💔💔💔 vimeo.com/1037583309/b7d…

Link in the initial post is broken ! nature.com/articles/s4146…

Here's our latest, led by Drs. Riaz Gillani & Ryan Collins - we studied a type of inherited genetic event (structural variants) + risk of developing certain cancers in kids: Dana-Farber News Dana-Farber Division of Population Sciences Boston Children's Broad Institute Science Magazine science.org/doi/10.1126/sc…

Here is a direct link to the paper rdcu.be/d5puQ

🔥 ctDNA Testing: Smoke Detector vs. Fire Investigation! 🔥 Nice analogy by Alex Wyatt 🧬🧬🧬Not all ctDNA tests serve the same purpose! Some detect cancer early (like a smoke detector), while others characterizetumor properties to guide treatment (like a fire

Elegant presentation from Alex Wyatt on the evolution of ctDNA detection and characterization! Session chaired by Dana-Farber Lank Center for Genitourinary Oncology's joaquim bellmunt and Barts Experimental Cancer Medicine Centre 's Bernadett Szabados #GU25 ASCO OncoAlert OncLive.com

Hot of the press in JNM ... with 10 years experience in Lutetium-177 PSMA radioligand therapy we describe a 1.3% incidence of myelodysplasia. We deep dive on each case with remarkable findings. One patient who participated in the ANZUP #TheraP trial had

Stunning research from Edmond Kwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative

On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the ANZUP phase II TheraP study, now published in Nature Medicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across

So many to thank that played an outsized role in making this possible. Special mention to close friends in Alex Wyatt lab for keeping me level-headed for last 2-3 years, Vancouver Prostate Centre for providing a home away from home, ANZUP for bridging my return home through

Substudy C of the Canadian Cancer Trials Group IND.234 PC_BETS—A phase II study of darolutamide selected by androgen-receptor ctDNA in patients with #mCRPC after prior ARPIs Study shows darolutamide has modest efficacy in #mCRPC post-ARPIs—but ctDNA AR profiling helps select

Clonal hematopoiesis (CH) in the ANZUP #TheraP study ASCO #ASCO25 presented by Asli Munzur ■ ¹⁷⁷Lu-PSMA-617: higher incidence of emergent CH compared to cabazitaxel chemotherapy ■ Most new clonal hematopoiesis mutations ¹⁷⁷Lu-PSMA-617 fall in DNA damage repair

Really honoured to get to collaborate on this CCTG PC-BETS study. and to present substudy G at #ASCO25 - carboplatin for mCRPC with DDR alterations detected in ctDNA (Alex Wyatt)

Understanding ctDNA technology applications for cancer detection and characterization. Alex Wyatt Vancouver Prostate Centre joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to break down the fundamentals of cell-free DNA and how ctDNA represents the tumor-derived portion of these fragments in the